Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earns Hold Rating from Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research note issued on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Stock Performance

Shares of Brainstorm Cell Therapeutics stock opened at $1.89 on Thursday. The business’s 50 day simple moving average is $1.98 and its 200 day simple moving average is $2.82. Brainstorm Cell Therapeutics has a 52-week low of $1.05 and a 52-week high of $11.89. The firm has a market cap of $10.78 million, a PE ratio of -0.39 and a beta of 0.26.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.